Literature DB >> 8810738

Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity.

M R Almeida1, M J Saraiva.   

Abstract

Thyroxine (T4) binding is a well-characterized function of transthyretin (TTR) and has been used to assess structural alterations of TTR variants. Most TTR variants deposit as amyloid fibrils originating different forms of hereditary amyloidosis. It has been hypothesized that amino acid substitutions in the TTR variants induce structural alterations that may be responsible for the amyloidogenicity of the mutant proteins. To test for structural alterations in TTR, we studied T4 binding to TTR variants both in whole serum and in isolated form obtained from heterozygotic carriers of amyloidogenic and non-amyloidogenic variants and compared the binding with the corresponding homozygotic recombinant variants. The results obtained indicated a normal T4 binding affinity for heterozygotic TTR Ala 49, TTR Leu 68, TTR Ala 71 and TTR Arg 102. Concerning TTR Pro 55 and TTR Met 111, we found a consistent decrease in binding affinity. These results were more pronounced for the equivalent recombinant proteins. Recombinant TTR Pro 55 did not show specific binding to T4 and recombinant TTR Met 111 presented very low binding affinity. Neither TTR Pro 55 nor TTR Met 111 are localized in the T4 binding channel, thus structural alterations induced by these mutations should be transmitted to the binding channel interfering with T4 binding. The results now reported, together with ongoing structural data by X-ray analyses on mutants Pro 55 and Met 111 and future binding studies with other ligands, will contribute to the elucidation of the structure and function of TTR, particularly in thyroid hormone metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8810738     DOI: 10.1530/eje.0.1350226

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

Review 1.  Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.

Authors:  M S Mimoto; S Refetoff
Journal:  J Endocrinol Invest       Date:  2019-07-27       Impact factor: 4.256

2.  Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin.

Authors:  Yraima Cordeiro; Julia Kraineva; Marisa Carvalho Suarez; Anna Gabriella Tempesta; Jeffery W Kelly; Jerson L Silva; Roland Winter; Debora Foguel
Journal:  Biophys J       Date:  2006-05-12       Impact factor: 4.033

3.  The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state.

Authors:  A D Ferrão-Gonzales; S O Souto; J L Silva; D Foguel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.

Authors:  M R Almeida; A M Damas; M C Lans; A Brouwer; M J Saraiva
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

5.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

Authors:  Simon E Kolstoe; Palma P Mangione; Vittorio Bellotti; Graham W Taylor; Glenys A Tennent; Stéphanie Deroo; Angus J Morrison; Alexander J A Cobb; Anthony Coyne; Margaret G McCammon; Timothy D Warner; Jane Mitchell; Raj Gill; Martin D Smith; Steven V Ley; Carol V Robinson; Stephen P Wood; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.